Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Other Non Operating Income (2016 - 2025)

Voyager Therapeutics' Other Non Operating Income history spans 10 years, with the latest figure at $404000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income changed 0.5% year-over-year to $404000.0; the TTM value through Dec 2025 reached $1.6 million, up 173.92%, while the annual FY2025 figure was $1.6 million, 165.11% up from the prior year.
  • Other Non Operating Income for Q4 2025 was $404000.0 at Voyager Therapeutics, up from $400000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $3.9 million in Q1 2021 and bottomed at -$1.6 million in Q2 2021.
  • The 5-year median for Other Non Operating Income is $401000.0 (2024), against an average of $552857.1.
  • The largest annual shift saw Other Non Operating Income plummeted 3341.3% in 2021 before it soared 2454.46% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at $585000.0 in 2021, then plummeted by 103.93% to -$23000.0 in 2022, then surged by 113.04% to $3000.0 in 2023, then skyrocketed by 13300.0% to $402000.0 in 2024, then increased by 0.5% to $404000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Other Non Operating Income are $404000.0 (Q4 2025), $400000.0 (Q3 2025), and $427000.0 (Q2 2025).